Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1998052577) GANGLIOSIDE GM3 INDUCED APOPTOSIS OF NEURAL CELLS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1998/052577 International Application No.: PCT/US1998/010390
Publication Date: 26.11.1998 International Filing Date: 22.05.1998
Chapter 2 Demand Filed: 04.12.1998
IPC:
A61K 31/70 (2006.01) ,A61K 31/7032 (2006.01) ,A61K 45/00 (2006.01) ,A61P 25/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7028
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7032
attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
CASE WESTERN RESERVE UNIVERSITY [US/US]; 10900 Euclid Avenue Cleveland, OH 44106, US (AllExceptUS)
MILLER, Robert, H. [GB/US]; US (UsOnly)
NOLL, Elizabeth [US/US]; US (UsOnly)
NAKASUJI, Yuji [JP/US]; US (UsOnly)
BLACK, Peter, McLaren [CA/US]; US (UsOnly)
Inventors:
MILLER, Robert, H.; US
NOLL, Elizabeth; US
NAKASUJI, Yuji; US
BLACK, Peter, McLaren; US
Agent:
MINNICH, Richard, J.; Fay, Sharpe, Beall, Fagan, Minnich & McKee 7th floor 1100 Superior Avenue Cleveland, OH 44114-2518, US
Priority Data:
60/047,43022.05.1997US
Title (EN) GANGLIOSIDE GM3 INDUCED APOPTOSIS OF NEURAL CELLS
(FR) APOPTOSE DE CELLULES NEURONALES INDUITE PAR UN GANGLIOSIDE GM3
Abstract:
(EN) The present invention relates to the ability of the ganglioside, GM3 to inhibit proliferation and induce apoptosis in proliferating CNS cells. The present invention further demonstrates the ability for GM3 to reduce cell numbers in primary cultures of rapidly proliferating human glial tumors and the 9L rat gliosarcoma cell line. In addition, GM3 is shown to have no effect on quiescent cultures of normal human CNS cells. A single injection of GM3 three days after intracranial implantation of tumor cells in a murine xenograft model system resulted in a significant increase in the symptom-free survival period of host animals. Therefore, GM3 is useful as a chemotherapeutic agent for human high grade gliomas.
(FR) La présente invention concerne l'aptitude du ganglioside, GM3, à inhiber la prolifération et à induire l'apoptose dans des cellules proliférantes CNS. L'invention concerne également l'aptitude de GM3 à réduire le nombre de cellules dans des cultures primaires de tumeurs gliales humaines proliférant rapidement et de la lignée cellulaire 9L du gliosarcome du rat. En outre, GM3 n'a aucun effet sur des cultures quiescentes de cellules CNS humaines. Une injection simple de GM3, trois jours après l'implantation intracrânienne de cellules tumorales dans un système murin constituant une hétérogreffe, provoque une augmentation significative de la période de survie sans symptôme chez des animaux hôtes. GM3 est, en outre, utilisé comme agent chimiothérapeutique destiné au traitement des gliomes très avancés chez l'homme.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
NZ501221IL133085EP0998294JP2002510291 CA2290598AU1998075003
AU2002300727